Thalidomide Boosts Anti-Tumor Effects of DMXAA
Author Information
Author(s): Cao Z, Joseph W R, Browne W L, Mountjoy K G, Palmer B D, Baguley B C, Ching L-M
Primary Institution: Auckland Cancer Society Research Centre, University of Auckland School of Medicine
Hypothesis
Does thalidomide enhance the anti-tumor activity of DMXAA by increasing TNF-α production?
Conclusion
Thalidomide significantly increases intra-tumoural TNF-α production and enhances the anti-tumor activity of DMXAA.
Supporting Evidence
- Co-administration of thalidomide with DMXAA increased anti-tumour activity.
- Thalidomide increased intra-tumoural TNF-α production approximately tenfold over DMXAA alone.
- Thalidomide did not enhance the anti-tumour action of LPS.
Takeaway
Thalidomide helps a medicine called DMXAA work better against tumors by making the body produce more of a substance that fights cancer.
Methodology
The study involved administering DMXAA and thalidomide to mice with tumors and measuring TNF-α production in various tissues.
Participant Demographics
Mice with established transplantable tumors were used in the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website